Fierce Biotech5d
Merck KGaA pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win
With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...
Endpoints News9d
Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug
Merck KGaA pays $85M for global rights to Abbisko's pimicotinib, a CSF-1R inhibitor for TGCT that competes with Daiichi ...
Nature27d
FDA approves CSF1R inhibitor for rare, non-cancerous joint tumours
It will compete with Daiichi Sankyo’s CSF1R inhibitor pexidartinib (Turalio), which secured FDA approval in TGCT in 2019. TGCT are rare, non-malignant tumours that form in and near joints.